The firm is a multi-family office investment and wealth management platform that combines traditional advisory services with direct investment and co-investment opportunities. The firm allocates capital across both direct company investments and third-party funds, providing exposure to high-growth sectors. The firm operates across Europe and the United States and maintains a flexible investment approach spanning multiple asset classes and stages.
The firm has an active focus on health technology and life sciences, including precision medicine, biotechnology, and select medical technology opportunities. The firm evaluates both companies and funds across early-stage and growth-stage investments, with an emphasis on scientific and clinical innovation that can drive meaningful long-term impact. Areas of interest include personalized healthcare, advanced therapeutic modalities, and technologies that improve diagnosis, treatment, and patient outcomes.
From a company and management team perspective, the firm partners with teams demonstrating strong domain expertise, execution capability, and strategic clarity. The firm prioritizes opportunities with robust scientific or technical foundations and credible pathways through development, regulatory processes, and commercialization. The firm invests as a collaborative partner, offering capital alongside strategic insight, co-investment flexibility, and access to a broader network of investors and industry relationships.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment